Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: A case report and literature review

Angiogenesis

Volumn 14, Issue 2, 2011, Pages 135-141

  Walraven, Maudy ^a,b   Witteveen, Petronella O ^b   Lolkema, Martijn P J ^b   Van Hillegersberg, R ^b   Voest, Emile E ^b   Verheul, H M W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Biological mechanisms; Gi perforation; Risk factors; TKI

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; C REACTIVE PROTEIN; CAPECITABINE; ERLOTINIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OXALIPLATIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ABSCESS; ADULT; AGED; ANEMIA; ANTIANGIOGENIC THERAPY; ANUS DISEASE; BACKACHE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CARCINOMATOUS PERITONITIS; CASE REPORT; CHOLESTEROL EMBOLISM; COLON CARCINOMA; COLON ULCER; COLONOSCOPY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG FEVER; DRUG WITHDRAWAL; ENTEROCOLITIS; ENZYME INHIBITION; FEMALE; FEMALE GENITAL TRACT TUMOR; GASTROINTESTINAL STROMAL TUMOR; HEMICOLECTOMY; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HYPERTENSION; ILEOSTOMY; KIDNEY CARCINOMA; LAPAROTOMY; LEUKOCYTE COUNT; LIVER METASTASIS; LIVER RESECTION; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN TARGETING; PULSE RATE; RECTUM HEMORRHAGE; REVIEW; RISK FACTOR; TUMOR NECROSIS;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BENZENESULFONATES; ENDOSCOPY; FEMALE; HUMANS; INDOLES; INTESTINAL PERFORATION; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES;

EID: 79959930110     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-010-9197-6     Document Type: Review

References (42)

1. Folkman J (1990) What is the evidence that tumors are angio-genesis dependent? J Natl Cancer Inst 82(1):4-6 (Pubitemid 20020880)
2. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25(4):581-611 (Pubitemid 39099316)
3. Folkman J (2003) Fundamental concepts of the angiogenic process. Curr Mol Med 3(7):643-651 (Pubitemid 37236406)
4. Han ES, Monk BJ (2007) What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105(1):3-6 (Pubitemid 46441477)
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 350(23):2335-2342 (Pubitemid 38702844)
6. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24(1):25-35 (Pubitemid 46630490)
7. De Mulder PH, Roigas J, Gillessen S, Srinivas S, Pisa P, Vogelzang N, Fountzilas G, Peschel C, Baum C, Escudier B (2006) A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 24(1), 18S(June 20 Suppl):abstr 4529
8. O'Reilly EM, Niedzwiecki D, Hollis DR, Bekaii-Saab TS, Pluard T, Duffy A, Overcash F, Ivy SP, Goldberg RM (2008) A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. J Clin Oncol 26 (May 20 Suppl):abstr 4515
9. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachere NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27(19):3133-3140
10. Min CJ, Liebes LF, Escalon J, Hamilton A, Yee H, Buckley MT, Wright JJ, Osman I, Polsky D, Pavlick AC (2008) Phase II trial of sorafenib (S [BAY 43-9006]) in metastatic melanoma (MM) including detection of BRAF with mutant specific-PCR (MS-PCR) and altered proliferation pathways-final outcome analysis. J Clin Oncol 26 (May 20 Suppl):abstr 9072
11. Wiebe L, Kasza KE, Maki RG, D'Adamo DR, Chow WA, Wade JL, Agamah E, Stadler WM, Vokes EE, Kindler HL (2008) Activity of sorafenib (SOR)inpatients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol 26(May 20 Suppl): abstr 10502
12. El-Khoueiry AB, Rankin C, Lenz HJ, Philip P, Rivkin SE, Blanke CD (2007) SWOG 0514: a phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. J Clin Oncol 25(1), 18S(June 20 Suppl):abstr 4639
13. Okamoto I, Miyazaki M, Morinaga R, Kaneda H, Ueda S, Hasegawa Y, Satoh T, Kawada A, Fukuoka M, Fukino K, Tanigawa T, Nakagawa K (2009) Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Investig New Drugs
14. Eng FC, Easson AM, Szentgyorgyi E, Knox JJ (2009) Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma. Eur J Surg Oncol 35(2):219-221
15. Peters NA, Richel DJ, Verhoeff JJ, Stalpers LJ (2008) Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol 26(14):2405-2406
16. Hur H, Park AR, Jee SB, Jung SE, Kim W, Jeon HM (2008) Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment. World J Gastroenterol 14(39):6096-6099
17. Ruka W, Rutkowski P, Nowecki Z, Dziewirski W (2009) Emergency surgery due to complications during molecular targeted therapy in advanced gastrointestinal stromal tumors (GIST). Ann Surg Oncol 15(Suppl 2):27(abstr 82)
18. Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24(15):2325-2331 (Pubitemid 46630664)
19. Flaig TW, Kim FJ, La Rosa FG, Breaker K, Schoen J, Russ PD (2009) Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Investig New Drugs 27(1):83-87
20. Frieling T, Heise J, Wassilew SW (2009) Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib. Deutsche medizinische Wochenschrift (1946) 134(28-29):e1-e2, 1464-1466
21. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol 20(11):1842-1847
22. Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14(6):1860-1869 (Pubitemid 46870935)
23. Sugrue M, Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn P, Steis R, Dong W, Sarkar S, Grothey A (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol 24(1), 18S (June 20 Suppl):abstr 3535
24. Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, Cormier JN (2008) Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 19(3):577-582 (Pubitemid 351325682)
25. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23(16):3697-3705
26. Parikh AA, Ellis LM (2008) Targeted therapies and surgical issues in gastrointestinal cancers. Targ Oncol 3:119-125
27. Tol J, Cats A, Mol L, Koopman M, Bos MM, van der Hoeven JJ, Antonini NF, van Krieken JH, Punt CJ (2008) Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Investig New Drugs 26(4):393-397
28. Yoshida M, Wakabayashi G, Ishikawa H, Kameyama K, Shimazu M, Tanabe M, Kawachi S, Kumai K, Kubota T, Otani Y, Saikawa Y, Sano K, Kitajima M (2003) A possible defensive mechanism in the basal region of gastric mucosa and the healing of erosions. Clin Hemorheol Microcirc 29(3-4):301-312 (Pubitemid 38130402)
29. Tarnawski AS (2005) Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 50(Suppl 1):S24-S33 (Pubitemid 41380795)
30. Malara B, Josko J, Tyrpien M, Malara P, Steplewska K (2005) Dynamics of changes in vascular endothelial growth factor (VEGF) expression and angiogenesis in stress-induced gastric ulceration in rats. J Physiol Pharmacol 56(2):259-271 (Pubitemid 40911092)
31. Mir O, Mouthon L, Alexandre J, Mallion JM, Deray G, Guillevin L, Goldwasser F (2007) Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst 99(1):85-86
32. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol 290(2):H560-H576
33. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25(33):5180-5186 (Pubitemid 350232248)
34. Simpkins F, Belinson JL, Rose PG (2007) Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 107(1):118-123 (Pubitemid 47464553)
35. Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, Akkerman JW, Pili R, Voest EE (2007) Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 13(18 Pt 1):5341-5347 (Pubitemid 47510358)
36. Verheul HM, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev 7(6):475-485 (Pubitemid 46809172)
37. Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, Orpana A, Ristimaki A, Heikinheimo M, Joensuu H, Alitalo K, Palotie A (1998) Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 80(1):171-175 (Pubitemid 28353517)
38. Selheim F, Holmsen H, Vassbotn FS (2002) Identification of functional VEGF receptors on human platelets. FEBS Lett 512(1-3):107-110 (Pubitemid 34164460)
39. Mohle R, Green D, Moore MA, Nachman RL, Rafii S (1997) Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 94(2):663-668 (Pubitemid 27053690)
40. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM (1997) Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3(12 Pt 1):2187-2190 (Pubitemid 28133134)
41. Okuda Y, Tsurumaru K, Suzuki S, Miyauchi T, Asano M, Hong Y, Sone H, Fujita R, Mizutani M, Kawakami Y, Nakajima T, Soma M, Matsuo K, Suzuki H, Yamashita K (1998) Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sci 63(6):477-484 (Pubitemid 28358111)
42. Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10(6):559-568